Low IDL causes: Difference between revisions

	Intermediate Density Lipoprotein Microchapters
Home
Patient information
Overview
Historical Perspective
Classification
Biochemistry
Physiology
Clinical Correlation
High IDL Epidemiology and Demographics Pathophysiology Causes Diseases Prognosis and Complications
Low IDL Epidemiology and Demographics Pathophysiology Causes Diseases Prognosis and Complications
Treatment
Medical Therapy
Primary Prevention
Secondary Prevention
Landmark Trials
Future or Investigational Therapies
Case Studies
Case #1
Low IDL causes On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Low IDL causes All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Low IDL causes
CDC on Low IDL causes
Low IDL causes in the news
Blogs on Low IDL causes
Directions to Hospitals Treating Intermediate density lipoprotein
Risk calculators and risk factors for Low IDL causes

← Older edit

VisualWikitext

Latest revision as of 13:29, 7 November 2013

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ogheneochuko Ajari, MB.BS, MS [2]

Overview

IDL, formed from the degradation of VLDL, transports a variety of triglyceride fats and cholesterol. Disorders that cause a decrease in IDL (or low IDL) are few and are limited to an enzyme deficiency or genetic causes and medication side effects.

Causes

Life Threatening Causes

Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.

There are no life threatening causes of low IDL.

Common Causes

Causes by Organ System

Cardiovascular	No underlying causes
Chemical/Poisoning	No underlying causes
Dental	No underlying causes
Dermatologic	No underlying causes
Drug Side Effect	Estrogen plus simvastatin combination therapy, extended-release niacin/laropiprant and simvastatin, lovastatin, pravastatin, statins
Ear Nose Throat	No underlying causes
Endocrine	No underlying causes
Environmental	No underlying causes
Gastroenterologic	Lipoprotein lipase deficiency
Genetic	Familial apolipoprotein AI and apolipoprotein CIII deficiency, lipoprotein lipase deficiency
Hematologic	No underlying causes
Iatrogenic	No underlying causes
Infectious Disease	No underlying causes
Musculoskeletal/Orthopedic	No underlying causes
Neurologic	No underlying causes
Nutritional/Metabolic	No underlying causes
Obstetric/Gynecologic	No underlying causes
Oncologic	No underlying causes
Ophthalmologic	No underlying causes
Overdose/Toxicity	No underlying causes
Psychiatric	No underlying causes
Pulmonary	No underlying causes
Renal/Electrolyte	No underlying causes
Rheumatology/Immunology/Allergy	No underlying causes
Sexual	No underlying causes
Trauma	No underlying causes
Urologic	No underlying causes
Miscellaneous	No underlying causes

Causes in Alphabetical Order

Estrogen plus simvastatin combination therapy^[1]
Extended-release niacin/laropiprant and simvastatin^[2]
Familial apolipoprotein AI and apolipoprotein CIII deficiency^[3]
Lipoprotein lipase deficiency
Lovastatin^[4]
Pravastatin^[5]^[6]
Statins

References

↑ Wakatsuki A, Okatani Y, Ikenoue N (2000). "Effects of combination therapy with estrogen plus simvastatin on lipoprotein metabolism in postmenopausal women with type IIa hypercholesterolemia". Atherosclerosis. 150 (1): 103–11. PMID 10781640.
↑ Ballantyne C, Gleim G, Liu N, Sisk CM, Johnson-Levonas AO, Mitchel Y (2012). "Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia". J Clin Lipidol. 6 (3): 235–43. doi:10.1016/j.jacl.2011.11.004. PMID 22658147.
↑ Forte TM, Nichols AV, Krauss RM, Norum RA (1984). "Familial apolipoprotein AI and apolipoprotein CIII deficiency. Subclass distribution, composition, and morphology of lipoproteins in a disorder associated with premature atherosclerosis". J Clin Invest. 74 (5): 1601–13. doi:10.1172/JCI111576. PMC 425337. PMID 6501564.
↑ Mack WJ, Krauss RM, Hodis HN (1996). "Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression". Arterioscler Thromb Vasc Biol. 16 (5): 697–704. PMID 8963728.
↑ Nishizawa Y, Shoji T, Tabata T, Inoue T, Morii H (1999). "Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients". Kidney Int Suppl. 71: S134–6. PMID 10412757.
↑ Lee SJ, Sacks FM (2003). "Effect of pravastatin on intermediate-density and low-density lipoproteins containing apolipoprotein CIII in patients with diabetes mellitus". Am J Cardiol. 92 (2): 121–4. PMID 12860210.

Template:WikiDoc Sources

[pmid10781640-1] Wakatsuki A, Okatani Y, Ikenoue N (2000). "Effects of combination therapy with estrogen plus simvastatin on lipoprotein metabolism in postmenopausal women with type IIa hypercholesterolemia". Atherosclerosis. 150 (1): 103–11. PMID 10781640.

[pmid22658147-2] Ballantyne C, Gleim G, Liu N, Sisk CM, Johnson-Levonas AO, Mitchel Y (2012). "Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia". J Clin Lipidol. 6 (3): 235–43. doi:10.1016/j.jacl.2011.11.004. PMID 22658147.

[pmid6501564-3] Forte TM, Nichols AV, Krauss RM, Norum RA (1984). "Familial apolipoprotein AI and apolipoprotein CIII deficiency. Subclass distribution, composition, and morphology of lipoproteins in a disorder associated with premature atherosclerosis". J Clin Invest. 74 (5): 1601–13. doi:10.1172/JCI111576. PMC 425337. PMID 6501564.

[pmid8963728-4] Mack WJ, Krauss RM, Hodis HN (1996). "Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression". Arterioscler Thromb Vasc Biol. 16 (5): 697–704. PMID 8963728.

[pmid10412757-5] Nishizawa Y, Shoji T, Tabata T, Inoue T, Morii H (1999). "Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients". Kidney Int Suppl. 71: S134–6. PMID 10412757.

[pmid12860210-6] Lee SJ, Sacks FM (2003). "Effect of pravastatin on intermediate-density and low-density lipoproteins containing apolipoprotein CIII in patients with diabetes mellitus". Am J Cardiol. 92 (2): 121–4. PMID 12860210.

[1]

[2]

[3]

[4]

[5]

[6]

@@ Line 1: / Line 1: @@
 __NOTOC__
 {{Template:Intermediate density lipoprotein}}
-{{CMG}}
+{{CMG}}; {{AE}} {{Ochuko}}
 ==Overview==
+IDL, formed from the degradation of [[VLDL]], transports a variety of triglyceride fats and cholesterol.  Disorders that cause a decrease in IDL (or low IDL) are few and are limited to an enzyme deficiency or genetic causes and medication side effects.
-==High IDL Causes==
+==Causes==
 ===Life Threatening Causes===
+Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
+There are no life threatening causes of low IDL.
 ===Common Causes===
+*[[Lipoprotein lipase deficiency]]
+*[[Statins]]
 ===Causes by Organ System===
-===Causes by Alphabetical Order===
+{|style="width:80%; height:100px" border="1"
+|style="height:100px"; style="width:25%" border="1" bgcolor="LightSteelBlue" |'''Cardiovascular'''
+|style="height:100px"; style="width:75%" border="1" bgcolor="Beige" | No underlying causes
+|-
+|bgcolor="LightSteelBlue"| '''Chemical/Poisoning'''
+|bgcolor="Beige"| No underlying causes
+|-
+|-bgcolor="LightSteelBlue"
+| '''Dental'''
+|bgcolor="Beige"| No underlying causes
+|-
+|-bgcolor="LightSteelBlue"
+| '''Dermatologic'''
+|bgcolor="Beige"| No underlying causes
+|-
+|-bgcolor="LightSteelBlue"
+| '''Drug Side Effect'''
+|bgcolor="Beige"| Estrogen plus simvastatin combination therapy, extended-release niacin/laropiprant and simvastatin, [[lovastatin]], [[pravastatin]], [[statins]]
+|-
+|-bgcolor="LightSteelBlue"
+| '''Ear Nose Throat'''
+|bgcolor="Beige"| No underlying causes
+|-
+|-bgcolor="LightSteelBlue"
+| '''Endocrine'''
+|bgcolor="Beige"| No underlying causes
+|-
+|-bgcolor="LightSteelBlue"
+| '''Environmental'''
+|bgcolor="Beige"| No underlying causes
+|-
+|-bgcolor="LightSteelBlue"
+| '''Gastroenterologic'''
+|bgcolor="Beige"| [[Lipoprotein lipase deficiency]]
+|-
+|-bgcolor="LightSteelBlue"
+| '''Genetic'''
+|bgcolor="Beige"| Familial apolipoprotein AI and apolipoprotein CIII deficiency, [[lipoprotein lipase deficiency]]
+|-
+|-bgcolor="LightSteelBlue"
+| '''Hematologic'''
+|bgcolor="Beige"| No underlying causes
+|-
+|-bgcolor="LightSteelBlue"
+| '''Iatrogenic'''
+|bgcolor="Beige"| No underlying causes
+|-
+|-bgcolor="LightSteelBlue"
+| '''Infectious Disease'''
+|bgcolor="Beige"| No underlying causes
+|-
+|-bgcolor="LightSteelBlue"
+| '''Musculoskeletal/Orthopedic'''
+|bgcolor="Beige"| No underlying causes
+|-
+|-bgcolor="LightSteelBlue"
+| '''Neurologic'''
+|bgcolor="Beige"| No underlying causes
+|-
+|-bgcolor="LightSteelBlue"
+| '''Nutritional/Metabolic'''
+|bgcolor="Beige"| No underlying causes
+|-
+|-bgcolor="LightSteelBlue"
+| '''Obstetric/Gynecologic'''
+|bgcolor="Beige"| No underlying causes
+|-
+|-bgcolor="LightSteelBlue"
+| '''Oncologic'''
+|bgcolor="Beige"| No underlying causes
+|-
+|-bgcolor="LightSteelBlue"
+| '''Ophthalmologic'''
+|bgcolor="Beige"| No underlying causes
+|-
+|-bgcolor="LightSteelBlue"
+| '''Overdose/Toxicity'''
+|bgcolor="Beige"| No underlying causes
+|-
+|-bgcolor="LightSteelBlue"
+| '''Psychiatric'''
+|bgcolor="Beige"| No underlying causes
+|-
+|-bgcolor="LightSteelBlue"
+| '''Pulmonary'''
+|bgcolor="Beige"| No underlying causes
+|-
+|-bgcolor="LightSteelBlue"
+| '''Renal/Electrolyte'''
+|bgcolor="Beige"| No underlying causes
+|-
+|-bgcolor="LightSteelBlue"
+| '''Rheumatology/Immunology/Allergy'''
+|bgcolor="Beige"| No underlying causes
+|-
+|-bgcolor="LightSteelBlue"
+| '''Sexual'''
+|bgcolor="Beige"| No underlying causes
+|-
+|-bgcolor="LightSteelBlue"
+| '''Trauma'''
+|bgcolor="Beige"| No underlying causes
+|-
+|-bgcolor="LightSteelBlue"
+| '''Urologic'''
+|bgcolor="Beige"| No underlying causes
+|-
+|-bgcolor="LightSteelBlue"
+| '''Miscellaneous'''
+|bgcolor="Beige"| No underlying causes
+|-
+|}
+===Causes in Alphabetical Order===
+*Estrogen plus simvastatin combination therapy<ref name="pmid10781640">{{cite journal| author=Wakatsuki A, Okatani Y, Ikenoue N| title=Effects of combination therapy with estrogen plus simvastatin on lipoprotein metabolism in postmenopausal women with type IIa hypercholesterolemia. | journal=Atherosclerosis | year= 2000 | volume= 150 | issue= 1 | pages= 103-11 | pmid=10781640 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10781640 }} </ref>
+*Extended-release niacin/laropiprant and simvastatin<ref name="pmid22658147">{{cite journal| author=Ballantyne C, Gleim G, Liu N, Sisk CM, Johnson-Levonas AO, Mitchel Y| title=Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia. | journal=J Clin Lipidol | year= 2012 | volume= 6 | issue= 3 | pages= 235-43 | pmid=22658147 | doi=10.1016/j.jacl.2011.11.004 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22658147 }} </ref>
+*Familial apolipoprotein AI and apolipoprotein CIII deficiency<ref name="pmid6501564">{{cite journal| author=Forte TM, Nichols AV, Krauss RM, Norum RA| title=Familial apolipoprotein AI and apolipoprotein CIII deficiency. Subclass distribution, composition, and morphology of lipoproteins in a disorder associated with premature atherosclerosis. | journal=J Clin Invest | year= 1984 | volume= 74 | issue= 5 | pages= 1601-13 | pmid=6501564 | doi=10.1172/JCI111576 | pmc=PMC425337 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6501564 }} </ref>
+*[[Lipoprotein lipase deficiency]]
+*[[Lovastatin]]<ref name="pmid8963728">{{cite journal| author=Mack WJ, Krauss RM, Hodis HN| title=Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression. | journal=Arterioscler Thromb Vasc Biol | year= 1996 | volume= 16 | issue= 5 | pages= 697-704 | pmid=8963728 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8963728 }} </ref>
+*[[Pravastatin]]<ref name="pmid10412757">{{cite journal| author=Nishizawa Y, Shoji T, Tabata T, Inoue T, Morii H| title=Effects of lipid-lowering drugs on intermediate-density lipoprotein in uremic patients. | journal=Kidney Int Suppl | year= 1999 | volume= 71 | issue= | pages= S134-6 | pmid=10412757 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10412757 }} </ref><ref name="pmid12860210">{{cite journal| author=Lee SJ, Sacks FM| title=Effect of pravastatin on intermediate-density and low-density lipoproteins containing apolipoprotein CIII in patients with diabetes mellitus. | journal=Am J Cardiol | year= 2003 | volume= 92 | issue= 2 | pages= 121-4 | pmid=12860210 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12860210 }} </ref>
+*[[Statins]]
 ==References==

v t e Lipopedia
Basic Science	Cholesterol • Triglyceride Lipoprotein metabolism and transport Lipoprotein: Chylomicron • Chylomicron remnant • HDL • IDL • LDL • Lipoprotein(a) • VLDL • Lipoprotein-X Apolipoprotein: APOA (1, 2, 4, 5) • APOB ( Apolipoprotein B-48, Apolipoprotein B-100) • APOC (1, 2, 3, 4) • APOD • APOE • APOH • APOJ • APOL • APOM • Apo(a) Lipoprotein receptor: LDL receptor • Soluble low density lipoprotein receptor-related protein (sLRP) • Apolipoprotein E Receptor 2 • Scavenger receptor • Scavenger receptor A • Scavenger receptor B • VLDL receptor Lipoprotein enzymes: Lipoprotein lipase • Lipoprotein-associated phospholipase A2 (Lp-PLA2) • Cholesterylester transfer protein ( Acetyl-CoA C-acyltransferase, Lecithin-cholesterol acyltransferase) • Microsomal triglyceride transfer protein • ABCA1 Genes: Low density lipoprotein receptor gene family • Microsomal triglyceride transfer protein • ABCA1
Lipoprotein Disorders	Lipoprotein disorders Primary lipoprotein disorders: Familial hyperchylomicronemia (Type I) • Familial hypercholesterolemia (Type IIA) • Familial combined hyperlipidemia (Type IIB) • Dysbetalipoproteinemia (Type III) • Primary hypertriglyceridemia (Type IV) • Mixed hyperlipoproteinemia (Type V) Secondary lipoprotein disorders
Abnormal Laboratory Lipid Profile	Low chylomicron • Low chylomicron remnant • Low HDL • Low IDL • Low LDL • Low lipoprotein(a) • Low VLDL High chylomicron • High chylomicron remnant • High HDL • High IDL • High LDL • High Lipoprotein(a) • High VLDL